JP2015517500A - Ｍｃｍ複合体を阻害するための方法および化合物ならびにガン処置におけるそれらの適用 - Google Patents

Ｍｃｍ複合体を阻害するための方法および化合物ならびにガン処置におけるそれらの適用 Download PDF

Info

Publication number
JP2015517500A
JP2015517500A JP2015511684A JP2015511684A JP2015517500A JP 2015517500 A JP2015517500 A JP 2015517500A JP 2015511684 A JP2015511684 A JP 2015511684A JP 2015511684 A JP2015511684 A JP 2015511684A JP 2015517500 A JP2015517500 A JP 2015517500A
Authority
JP
Japan
Prior art keywords
cells
mcm
17beta
deacetyltanginine
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015511684A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517500A5 (enExample
Inventor
リアン チュン
リアン チュン
ジアン ジホン
ジアン ジホン
ワン ジイ
ワン ジイ
ユー ジリン
ユー ジリン
ワン ジンロン
ワン ジンロン
バイ リピン
バイ リピン
Original Assignee
ザ ホン コン ユニバーシティ オブ サイエンス アンド テクノロジイ
ザ ホン コン ユニバーシティ オブ サイエンス アンド テクノロジイ
ホン コン バプティスト ユニバーシティ
ホン コン バプティスト ユニバーシティ
マカウ ユニバーシティ オブ サイエンス アンド テクノロジイ
マカウ ユニバーシティ オブ サイエンス アンド テクノロジイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ホン コン ユニバーシティ オブ サイエンス アンド テクノロジイ, ザ ホン コン ユニバーシティ オブ サイエンス アンド テクノロジイ, ホン コン バプティスト ユニバーシティ, ホン コン バプティスト ユニバーシティ, マカウ ユニバーシティ オブ サイエンス アンド テクノロジイ, マカウ ユニバーシティ オブ サイエンス アンド テクノロジイ filed Critical ザ ホン コン ユニバーシティ オブ サイエンス アンド テクノロジイ
Publication of JP2015517500A publication Critical patent/JP2015517500A/ja
Publication of JP2015517500A5 publication Critical patent/JP2015517500A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2015511684A 2012-05-09 2013-05-09 Ｍｃｍ複合体を阻害するための方法および化合物ならびにガン処置におけるそれらの適用 Pending JP2015517500A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261644442P 2012-05-09 2012-05-09
US61/644,442 2012-05-09
PCT/US2013/040287 WO2013169989A1 (en) 2012-05-09 2013-05-09 Method and compounds for inhibiting the mcm complex and their application in cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018002988A Division JP2018100274A (ja) 2012-05-09 2018-01-11 Ｍｃｍ複合体の形成を阻害する方法および抗ガン化合物についてスクリーニングする方法

Publications (2)

Publication Number Publication Date
JP2015517500A true JP2015517500A (ja) 2015-06-22
JP2015517500A5 JP2015517500A5 (enExample) 2016-06-23

Family

ID=49551267

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2015511684A Pending JP2015517500A (ja) 2012-05-09 2013-05-09 Ｍｃｍ複合体を阻害するための方法および化合物ならびにガン処置におけるそれらの適用
JP2018002988A Pending JP2018100274A (ja) 2012-05-09 2018-01-11 Ｍｃｍ複合体の形成を阻害する方法および抗ガン化合物についてスクリーニングする方法
JP2019237597A Pending JP2020073544A (ja) 2012-05-09 2019-12-27 Ｍｃｍ複合体の形成を阻害する方法および抗ガン化合物についてスクリーニングする方法
JP2021150771A Pending JP2021193132A (ja) 2012-05-09 2021-09-16 Ｍｃｍ複合体の形成を阻害する方法および抗ガン化合物についてスクリーニングする方法
JP2023154199A Pending JP2024001049A (ja) 2012-05-09 2023-09-21 Ｍｃｍ複合体の形成を阻害する方法および抗ガン化合物についてスクリーニングする方法
JP2025134199A Pending JP2025169320A (ja) 2012-05-09 2025-08-12 Ｍｃｍ複合体の形成を阻害する方法および抗ガン化合物についてスクリーニングする方法

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2018002988A Pending JP2018100274A (ja) 2012-05-09 2018-01-11 Ｍｃｍ複合体の形成を阻害する方法および抗ガン化合物についてスクリーニングする方法
JP2019237597A Pending JP2020073544A (ja) 2012-05-09 2019-12-27 Ｍｃｍ複合体の形成を阻害する方法および抗ガン化合物についてスクリーニングする方法
JP2021150771A Pending JP2021193132A (ja) 2012-05-09 2021-09-16 Ｍｃｍ複合体の形成を阻害する方法および抗ガン化合物についてスクリーニングする方法
JP2023154199A Pending JP2024001049A (ja) 2012-05-09 2023-09-21 Ｍｃｍ複合体の形成を阻害する方法および抗ガン化合物についてスクリーニングする方法
JP2025134199A Pending JP2025169320A (ja) 2012-05-09 2025-08-12 Ｍｃｍ複合体の形成を阻害する方法および抗ガン化合物についてスクリーニングする方法

Country Status (9)

Country Link
US (1) US11648258B2 (enExample)
EP (2) EP4248978A3 (enExample)
JP (6) JP2015517500A (enExample)
CN (2) CN110412285B (enExample)
AU (1) AU2013259486B2 (enExample)
CA (2) CA3111702C (enExample)
ES (1) ES2949335T3 (enExample)
IN (1) IN2014MN02513A (enExample)
WO (1) WO2013169989A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019283946B2 (en) * 2017-05-19 2021-05-20 Enkang Pharmaceuticals (Guangzhou), Ltd. Crystal characteristics, preparation processes and anticancer applications of 17beta-neriifolin crystal forms
CN108948119B (zh) 2017-05-19 2023-11-21 恩康药业科技（广州）有限公司 黄夹次甙乙多晶型的晶型特征、制备方法及在抗癌上的应用
CN114177189A (zh) * 2019-03-27 2022-03-15 天津中医药大学 黄夹次乙苷作为抗肿瘤药物的应用
WO2025077888A1 (zh) * 2023-10-13 2025-04-17 恩康药业科技（广州）有限公司 一种适合外用的化合物及药物组合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004131435A (ja) * 2002-10-11 2004-04-30 Mitsubishi Chemicals Corp 抗癌剤のスクリーニング方法及び組織の癌化の判定方法
JP2006514545A (ja) * 2002-10-18 2006-05-11 ヴォルフガング ベルデル， 異常局在化分子およびその使用
JP2008525479A (ja) * 2004-12-22 2008-07-17 オークランド ユニサービシス リミテッド トレフォイル因子およびそれを用いた増殖性疾患の処置方法
JP2009515932A (ja) * 2005-11-18 2009-04-16 アンスティテュート キュリー カルシニューリンの調節に基づく癌を処置するための新しい方法
US20110311651A1 (en) * 2008-12-10 2011-12-22 Sloan-Kettering Institute For Cancer Research Cardenolides for the treatment of ocular cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0592990A (ja) 1991-08-06 1993-04-16 Taisho Pharmaceut Co Ltd カルデノライド誘導体
WO2002014343A1 (en) 2000-08-17 2002-02-21 Terness, Peter Bufadienolide derivatives and use as immunosuppressive, antiinflammatory and analgesic agents
US8318922B2 (en) 2002-08-29 2012-11-27 The Hong Kong Polytechnic University Treatment and prevention of hyperproliferative conditions in humans and antisense oligonucleotide inhibition of human replication-initiation proteins
US7393950B2 (en) 2002-08-29 2008-07-01 Hong Kong University Of Science & Technology Antisense oligonucleotides targeted to human CDC45
US20070207120A1 (en) * 2004-04-14 2007-09-06 Sarah Drayton Selective Killing Of Cancer Cells By Induction Of Acetyltransferase Via Tnf-Alpha And Il-6
US20090018088A1 (en) * 2006-10-27 2009-01-15 University Of Louisville Research Foundation Treating cancer with cardiac glycosides
CN101683359B (zh) * 2008-09-28 2012-05-09 上海秀新臣邦医药科技有限公司 一种治疗肿瘤的中药组合物及其制备方法
CN101726577A (zh) * 2008-10-13 2010-06-09 中山大学 通过干扰巢蛋白表达来筛选抑制肿瘤增殖和促进细胞凋亡的药物的方法
CN102219821A (zh) 2011-05-05 2011-10-19 沈阳药科大学 一类强心苷类化合物及其抗肿瘤用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004131435A (ja) * 2002-10-11 2004-04-30 Mitsubishi Chemicals Corp 抗癌剤のスクリーニング方法及び組織の癌化の判定方法
JP2006514545A (ja) * 2002-10-18 2006-05-11 ヴォルフガング ベルデル， 異常局在化分子およびその使用
JP2008525479A (ja) * 2004-12-22 2008-07-17 オークランド ユニサービシス リミテッド トレフォイル因子およびそれを用いた増殖性疾患の処置方法
JP2009515932A (ja) * 2005-11-18 2009-04-16 アンスティテュート キュリー カルシニューリンの調節に基づく癌を処置するための新しい方法
US20110311651A1 (en) * 2008-12-10 2011-12-22 Sloan-Kettering Institute For Cancer Research Cardenolides for the treatment of ocular cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CANCER SCIENCE, vol. 99, no. 12, JPN6017002758, 2008, pages 2467 - 2476, ISSN: 0003491950 *
CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 52, no. 8, JPN6017002756, 2004, pages 1023 - 1025, ISSN: 0003491949 *
GENES TO CELLS, vol. 1, JPN6017002763, 1996, pages 977 - 993, ISSN: 0003491952 *
JOURNAL OF ETHNOPHARMACOLOGY, vol. 141, JPN6017002761, 2011, pages 692 - 700, ISSN: 0003491951 *

Also Published As

Publication number Publication date
AU2013259486A1 (en) 2014-12-18
EP4248978A2 (en) 2023-09-27
CA3111702C (en) 2025-03-18
EP2846807A4 (en) 2016-07-27
CA3111702A1 (en) 2013-11-14
EP2846807B1 (en) 2023-06-07
CA2873283C (en) 2021-05-04
US20150099712A1 (en) 2015-04-09
WO2013169989A1 (en) 2013-11-14
AU2013259486B2 (en) 2019-12-12
JP2021193132A (ja) 2021-12-23
JP2025169320A (ja) 2025-11-12
EP2846807A1 (en) 2015-03-18
ES2949335T3 (es) 2023-09-27
EP4248978A3 (en) 2023-11-08
CN104736157A (zh) 2015-06-24
JP2020073544A (ja) 2020-05-14
JP2018100274A (ja) 2018-06-28
IN2014MN02513A (enExample) 2015-07-17
JP2024001049A (ja) 2024-01-09
EP2846807C0 (en) 2023-06-07
CN104736157B (zh) 2019-06-11
US11648258B2 (en) 2023-05-16
CN110412285A (zh) 2019-11-05
CA2873283A1 (en) 2013-11-14
CN110412285B (zh) 2022-11-15

Similar Documents

Publication Publication Date Title
JP2024001049A (ja) Ｍｃｍ複合体の形成を阻害する方法および抗ガン化合物についてスクリーニングする方法
Winnicka et al. Antiproliferative activity of derivatives of ouabain, digoxin and proscillaridin A in human MCF-7 and MDA-MB-231 breast cancer cells
Emanuele et al. Sodium butyrate induces apoptosis in human hepatoma cells by a mitochondria/caspase pathway, associated with degradation of β-catenin, pRb and Bcl-XL
Li et al. Solamargine induces apoptosis associated with p53 transcription-dependent and transcription-independent pathways in human osteosarcoma U2OS cells
Das et al. Mahanine, A dietary phytochemical, represses mammary tumor burden in rat and inhibits subtype regardless breast cancer progression through suppressing self-renewal of breast cancer stem cells
Li et al. The effect of dihydroartemisinin on the malignancy and epithelial-mesenchymal transition of gastric cancer cells
Xu et al. In vitro and in vivo antitumor effects of plant-derived miliusanes and their induction of cellular senescence
Du et al. Steroidal glycoalkaloids from Solanum lyratum inhibit the pro-angiogenic activity of A549-derived exosomes
Lu et al. Inhibition of BAG3 enhances the anticancer effect of shikonin in hepatocellular carcinoma
Wang et al. Liquiritigenin inhibits the migration, invasion, and EMT of prostate cancer through activating ER stress
Han et al. A new semisynthetic 1-O-acetyl-6-O-lauroylbritannilactone induces apoptosis of human laryngocarcinoma cells through p53-dependent pathway
Tahtamouni et al. Cephalostatin 1 analogues activate apoptosis via the endoplasmic reticulum stress signaling pathway
Aghaei et al. Pimpinelol, a novel atypical sesquiterpene lactone from Pimpinella haussknechtii fruits with evaluation of endoplasmic reticulum stress in breast cancer cells
Goswami et al. Antiproliferative potential of a novel parthenin analog P16 as evident by apoptosis accompanied by down-regulation of PI3K/AKT and ERK pathways in human acute lymphoblastic leukemia MOLT-4 cells
Zhang et al. Podophyllotoxin–pterostilbene fused conjugates as potential multifunctional antineoplastic agents against human uveal melanoma cells
US20230293564A1 (en) Method and compounds for inhibiting the MCM complex and their application in cancer treatment
Park et al. Synthesis of apoptotic chalcone analogues in HepG2 human hepatocellular carcinoma cells
Huang et al. Phragmunis a suppresses glioblastoma through the regulation of MCL1-FBXW7 by blocking ELK1-SRF complex-dependent transcription
HK40100635A (en) Method and compounds for inhibiting the mcm complex and their application in cancer treatment
HK40016841B (en) Method and compounds for inhibiting the mcm protein complex and their application in cancer treatment
HK40016841A (en) Method and compounds for inhibiting the mcm protein complex and their application in cancer treatment
Wang et al. Role of mimic of manganese superoxide dismutase in proliferation and apoptosis of gastric carcinoma BGC-823 cells in vitro and in vivo
Laksmiani et al. Brazilein Increased Cytotoxic Activity of Doxorubicin on MCF-7/DOX Cells
JP6931889B2 (ja) 白血病幹細胞のニッチ形成抑制活性を有する海洋生物由来の抽出物、化合物及び医薬組成物
WO2013074905A2 (en) Compounds, compositions, pharmaceutical compositions, and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160506

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160506

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170502

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170802

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170913